Evaluation of cellular immune responses in subjects chronically infected with HIV type 1
- PMID: 17263635
- DOI: 10.1089/aid.2006.0114
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1
Abstract
The importance of host cellular immune responses, particularly CD8(+) cytotoxic T-lymphocyte (CTL) responses, in control of human immunodeficiency virus type 1 (HIV-1) infection has been demonstrated in many clinical studies. These studies, along with vaccination challenge studies in rhesus macaques, indicate the importance of cellular immune responses against HIV-1. Toward this end, we evaluated anti-HIV-1 cellular immune responses in a cohort of 54 subjects who were chronically infected with HIV-1. By validation of IFN-gamma ELISpot assay, we established a dual cut-off criterion for scoring a positive response. The magnitude and frequency of cellular immune responses were measured against HIV-1 antigens (Gag, Pol, Nef, Rev, and Tat), using synthetic peptides as antigens in ELISpot assay. Here we showed that HIV-1 Gag, Pol, and Nef were frequent targets of T cell responses in these subjects, whereas Tat and Rev were less frequently recognized. We further evaluated the possible association between host cellular immune responses and corresponding plasma viral loads in this cohort. By performing ranking correlation analysis, we demonstrated a positive correlation between host viral loads and ELISpot responses of HIV Gag and Pol in untreated subjects. For the subjects under antiviral regimens, however, we did not find any significant association. Our findings suggest that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection.
Similar articles
-
Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men.AIDS Res Hum Retroviruses. 1995 Apr;11(4):481-9. doi: 10.1089/aid.1995.11.481. AIDS Res Hum Retroviruses. 1995. PMID: 7632463
-
Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37. doi: 10.1089/aid.1998.14.925. AIDS Res Hum Retroviruses. 1998. PMID: 9686639
-
Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.J Infect Dis. 2005 Sep 1;192(5):749-59. doi: 10.1086/432547. Epub 2005 Jul 27. J Infect Dis. 2005. PMID: 16088824
-
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.J Virol. 2002 Mar;76(5):2298-305. doi: 10.1128/jvi.76.5.2298-2305.2002. J Virol. 2002. PMID: 11836408 Free PMC article.
-
Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.J Virol. 2007 Sep;81(17):9061-71. doi: 10.1128/JVI.00117-07. Epub 2007 Jun 20. J Virol. 2007. PMID: 17582003 Free PMC article.
Cited by
-
Clade A HIV-1 Gag-specific T cell responses are frequent but do not correlate with viral loads in a cohort of treatment-naive HIV-infected individuals living in Guinea-Bissau.Clin Vaccine Immunol. 2012 Dec;19(12):1999-2001. doi: 10.1128/CVI.00399-12. Epub 2012 Oct 17. Clin Vaccine Immunol. 2012. PMID: 23081817 Free PMC article. No abstract available.
-
Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway.Mol Ther. 2010 Mar;18(3):594-600. doi: 10.1038/mt.2009.230. Epub 2009 Oct 13. Mol Ther. 2010. PMID: 19826405 Free PMC article.
-
Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.Vaccine. 2019 Jan 3;37(1):113-122. doi: 10.1016/j.vaccine.2018.11.024. Epub 2018 Nov 17. Vaccine. 2019. PMID: 30459072 Free PMC article.
-
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299. J Infect Dis. 2010. PMID: 20078213 Free PMC article. Clinical Trial.
-
Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.Clin Vaccine Immunol. 2008 Feb;15(2):267-76. doi: 10.1128/CVI.00284-07. Epub 2007 Dec 12. Clin Vaccine Immunol. 2008. PMID: 18077621 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials